Get the Stockscreener App
90.98
3.05%
2.69
After Hours:
90.98
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $90.98, with a volume of 1.21M.
It is up +3.05% in the last 24 hours and up +9.79% over the past month.
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
See More
Previous Close:
$88.29
Open:
$89
24h Volume:
1.21M
Relative Volume:
0.93
Market Cap:
$10.56B
Revenue:
$2.77B
Net Income/Loss:
$286.61M
P/E Ratio:
38.71
EPS:
2.35
Net Cash Flow:
$524.11M
1W Performance:
-2.57%
1M Performance:
+9.79%
6M Performance:
-4.09%
1Y Performance:
-25.13%
1-Day Range:
$88.62
$91.44
1-Week Range:
$88.06
$94.64
52-Week Range:
$81.36
$129.50
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
90.98 | 10.25B | 2.77B | 286.61M | 524.11M | 2.35 |
|
TMO
Thermo Fisher Scientific Inc
|
524.58 | 198.17B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
205.14 | 144.97B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
633.32 | 49.29B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
138.23 | 38.73B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
203.77 | 33.69B | 15.70B | 1.24B | 2.01B | 6.9036 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
How Revvity Inc. (PKN) stock reacts to Fed tightening2025 Trading Volume Trends & Weekly High Return Stock Opportunities - newser.com
Revvity's Moat Rating Downgraded as Portfolio Transformations Weigh on Economic Returns - Morningstar
Revvity Closes Second Massachusetts Site, Increases Layoffs Amid Operational Consolidation - Boston Real Estate Times
Applying big data sentiment scoring on Revvity Inc.Weekly Trade Analysis & Fast Exit and Entry Strategy Plans - newser.com
Can Revvity Inc. stock withstand economic slowdownJuly 2025 Market Mood & Real-Time Stock Movement Alerts - newser.com
Leerink Partners Adjusts Revvity Price Target to $120 From $110, Maintains Outperform Rating - MarketScreener
Why analysts remain bullish on Revvity Inc. stockPortfolio Update Summary & Real-Time Chart Pattern Alerts - newser.com
Will Revvity Inc. rebound enough to break evenWeekly Trend Summary & High Return Trade Opportunity Guides - newser.com
Sivik Global Healthcare LLC Purchases Shares of 45,000 Revvity Inc. $RVTY - MarketBeat
Revvity Inc. $RVTY Shares Bought by Triodos Investment Management BV - MarketBeat
Revvity, Inc. Experiences Evaluation Revision Amid Mixed Market Signals and Performance Challenges - Markets Mojo
Major Mass. biomanufacturer closes 2nd site, lays off more workers - The Business Journals
Medpace and Revvity Stocks Trade Down, What You Need To Know - TradingView
Revvity Inc. stock momentum explained2025 Earnings Impact & Daily Market Momentum Tracking - newser.com
Using fundamentals and technicals on Revvity Inc.Market Sentiment Summary & Verified Technical Trade Signals - newser.com
How to track smart money flows in Revvity Inc.IPO Watch & Safe Capital Growth Trade Ideas - newser.com
RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes - sharewise.com
Revvity Inc. stock trend outlook and recovery pathFed Meeting & Risk Managed Investment Strategies - newser.com
Will Revvity Inc. see short term momentumJuly 2025 Update & Expert Curated Trade Ideas - newser.com
Best data tools to analyze Revvity Inc. stock2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - newser.com
Is Revvity Inc. stock a top pick for value investorsWeekly Trend Summary & AI Powered Market Trend Analysis - newser.com
Will Revvity Inc. (PKN) stock enhance shareholder valueWeekly Investment Recap & Stock Timing and Entry Methods - newser.com
Will Revvity Inc. stock sustain high P E ratios2025 Buyback Activity & Daily Profit Focused Screening - newser.com
Chart based analysis of Revvity Inc. trends2025 Technical Patterns & Real-Time Volume Analysis Alerts - newser.com
Evercore ISI Group Maintains Revvity (RVTY) Outperform Recommendation - Nasdaq
Evercore ISI Lowers Revvity (NYSE:RVTY) Price Target to $106.00 - MarketBeat
Evercore ISI Adjusts Revvity Price Target to $106 From $108, Maintains Outperform Rating - MarketScreener
Drake & Associates LLC Acquires 12,553 Shares of Revvity Inc. $RVTY - MarketBeat
Revvity to Hold Earnings Call on Monday, October 27, 2025 - PharmiWeb.com
Revvity, Sanofi team on early Type 1 detection; Kihealth raises funds for diabetes test rollout - MedTech Dive
Is Revvity Inc. stock undervalued vs historical averagesBuy Signal & Community Verified Trade Alerts - newser.com
Revvity (RVTY) Is Up 11.9% After Announcing Sanofi Alliance to Expand Diabetes Diagnostics Portfolio - Sahm
What drives Revvity Inc stock priceShort-Term Trading Alerts & These Picks Are Just One Breakout Away - earlytimes.in
Can a trend reversal in Revvity Inc. lead to recoveryChart Signals & Stock Timing and Entry Methods - newser.com
Using AI based signals to follow Revvity Inc.Trade Volume Report & Risk Controlled Daily Trade Plans - newser.com
A Fresh Look at Revvity (RVTY) Valuation After Sanofi Partnership in Early Diabetes Screening - Sahm
Revvity to develop type 1 diabetes early detection assay with Sanofi - Investing.com Nigeria
Automated trading signals detected on Revvity Inc.Trade Signal Summary & Safe Entry Trade Signal Reports - newser.com
Order flow analysis tools used on Revvity Inc.July 2025 WrapUp & Weekly Setup with ROI Potential - newser.com
Lucem, Revvity partner with Sanofi for early T1D detection - BioWorld MedTech
Barclays Adjusts Revvity (RVTY) Price Target, Maintains Overweig - GuruFocus
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes - PharmiWeb.com
Barclays Maintains Revvity (RVTY) Overweight Recommendation - Nasdaq
Revvity Expands Type 1 Diabetes Program With Sanofi Support - Nasdaq
Sanofi (SNY) Supports Revvity's Expansion in Type 1 Diabetes Assay - GuruFocus
Revvity Launches Program to Expand Type 1 Diabetes Diagnosis Offering - MarketScreener
Barclays Adjusts Price Target on Revvity to $100 From $110, Maintains Overweight Rating - MarketScreener
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):